Guangrong Zheng

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of <i>JAK2</i>-mutated post-MPN AML

Abstract 2469: PROTAC mediated NR4A1 degradation as a novel strategy for cancer immunotherapy

Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

Synthesis and Liver Microsomal Metabolic Stability Studies of a Fluorine‐Substituted δ‐Tocotrienol Derivative

Deuteration of the farnesyl terminal methyl groups of δ-tocotrienol and its effects on the metabolic stability and ability of inducing G-CSF production